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Abstract
PURPOSE—To explore whether disparities in outcomes exist between African-American (AA) 
and Caucasian (CS) men with low-grade prostate cancer (PCa) and similar Cancer of the Prostate 
Risk Assessment post-Surgery (CAPRA-S) features following prostatectomy (RP)
METHODS—The overall cohort consisted of 1,265 men (234 AA, and 1,031 CS) who met 
National comprehensive cancer network (NCCN) criteria for low-intermediate risk PCa and 
underwent RP between 1990 and 2012. We first evaluated whether clinical factors were associated 
with adverse pathologic outcomes and freedom from biochemical failure (FFbF) using the entire 
cohort. Next, we studied a subset of 705 men (112 AA, and 593 CS) who had pathologic Gleason 
score ≤6 (low-grade disease). Using this cohort, we determined whether race impacted FFbF in 
men with prostatectomy-proven low-grade disease and similar CAPRA-S score.
RESULTS—With a median follow up time of 27 months, the overall 7-year FFbF rate was 86% 
vs. 79% in CS and AA men, respectively (p=0.035). There was no significant difference in ≥1 
adverse pathologic features between CS vs. AA men (27% vs. 31%; P =0.35) or CAPRA-S score 
(p=0.28). In the subset analysis of patients with low-grade disease, AA race was associated with 
worse FFbF outcomes (p=0.002). Furthermore, AA race was a significant predictor of FFbF in 
men with low-grade disease (HR 2.01, 95%CI 1.08–3.72; p=0.029).
CONCLUSIONS—AA race is a predictor of worse FFbF outcomes in men with low-grade 
disease after RP. These results suggest that a subset of AA men with low-grade disease may 
benefit from more aggressive treatment.
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Introduction
Men of African descent are known to experience greater incidence of and mortality from 
PCa than men of other races[1]. AA men have been shown to experience PCa at an earlier 
age as compared to CS men. Furthermore, AA men often present with higher grade and 
stage of disease at time of diagnosis[2]. This observation has been partly attributed to socio-
economic factors and inadequate access to healthcare[3]. However, there is recent evidence 
suggesting that differences in genetic susceptibility play a major role in this disparity[4, 5].
Due to the relatively indolent nature of most PCa diagnosed in the US, the decision-making 
process for determining whether to pursue active surveillance, or alternative management 
options, is complicated by the balance between life expectancy, comorbidities, clinical 
benefits, as well as the side effects of treatment[6]. The ability to predict clinical outcomes is 
critical in recommending appropriate treatment options for PCa patients. Current NCCN 
guidelines recommend active surveillance as the preferred option for very low-risk PCa in 
men, defined as PSA <10 ng/ml, clinical stage ≤T1c. Gleason score (GS) ≤6, positive cores 
≤2, and cancer involvement of ≤50% per core. The goal of these recommendations is to 
prevent overtreatment of indolent cancers while identifying patients who develop disease 
progression and offering treatment with curative intent. However, most predictive tools 
currently used to risk-stratify PCa patients for treatment recommendations have not been 
developed or validated in AA men[7]. Furthermore, randomized clinical trials reporting on 
low-risk prostate treatment outcomes have been unable to effectively address whether 
interventions depend on race due to inadequate numbers of AA participants[8].
Whether AA race acts as a prognostic factor for freedom from biochemical failure (FFbF) in 
patients with pathologic GS ≤6 disease (referred to here as low-grade disease) and minimal 
adverse pathologic features after prostatectomy (RP) is poorly understood. The goal of this 
study is to determine whether disparities in adverse pathologic features and FFbF outcomes 
exist among an identical cohort of AA and CS men using a prospective cohort of PCa 
patients treated with RP.
Patients and Methods
Patient selection
The present study is a retrospective analysis of a prospective cohort of 2,012 men (298 AA, 
1,673 CS and 41 Other race) with PCa treated with RP at the University of Pennsylvania 
Health System (UPHS; Philadelphia, PA) recruited to the Study of Clinical Outcomes, Risk 
and Ethnicity (SCORE) between 1990 and 2012[9]. Patients without adequate preclinical 
data including initial PSA, or biopsy GS at diagnosis were excluded from the analysis 
(N=457). Patients of non-CS and non-AA ethnicity were excluded (N=41). Patients with 
>T3 tumors, or a GS between 7(4+3) and 10, or a PSA level ≥20 ng/ml, or patients found to 
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have regional lymph node metastasis on imaging or following bilateral pelvic lymph node 
dissection were excluded from the study (N=249). The remaining 1,265 patients comprising 
the overall cohort who met NCCN criteria for low-intermediate risk PCa with biopsy GS ≤ 7 
(3+4), T-stage ≤ T2c, PSA ≤ 20ng/ml and underwent RP were selected for this study[10]. Of 
the 1,265 patients, a subset of 705 men (112 AA, and 593 CS) with pathologic GS ≤6 (low-
grade disease determined post-RP), and were further analyzed in this study. We selected 
low-intermediate risk patients in the overall cohort in order to capture patients with biopsy 
GS 7 (3+4) who were downgraded to pathologic GS 6 (3+3) following RP.
Preoperative staging
Patients were evaluated at time of diagnosis by a thorough history and physical examination 
(including digital rectal examination [DRE]) followed by routine laboratory studies, 
including serum PSA levels, and GS determined by needle biopsy and reviewed at the 
UPHS. All patients were staged according to the 1992 American Joint Committee on Cancer 
staging system[11].
Treatment
Surgical treatment consisted of a radical retropubic prostatectomy or robotic-assisted radical 
prostatectomy, and bilateral pelvic lymph node sampling. All pathology slides were prepared 
as per standard institutional protocol. Prostatectomy specimen was initially coated with india 
ink and fixed in formalin. The whole gland was step sectioned at 3 mm intervals and the 
resulting sections were fixed into tissue cassettes. Tissue sections were embedded in paraffin 
blocks, from which sections were prepared and stained with hematoxylin and eosin for 
routine histological analysis by a dedicated GU pathologist. Adverse pathologic features 
consisting of extraprostatic extension (EPE), seminal vesicle invasion (SVI), and surgical 
margin status (SM) were noted and recorded. At the discretion of the treating physician, 
patients with adverse pathologic features including EPE, SVI or positive surgical margins 
were treated with adjuvant radiation therapy (RT) and/or androgen depravation therapy 
(ADT). ADT consisted of a gonadotropin-releasing hormone agonist (leuprolide acetate or 
goserelin acetate) with or without an antiandrogen (e.g. flutamide, bicalutamide).
Follow-Up and treatment endpoints
Patient information at each follow-up visit including DRE and serial PSA values were noted 
and recorded. PSA failure was defined as a single PSA≥0.2ng/ml along with documentation 
of failure by a physician or when two consecutive PSA values of 0.2ng/ml were obtained 
after an undetectable value. Start of the prospective follow-up (i.e., time zero) was defined at 
the date of surgery for all patients. If PSA was never undetectable postoperatively, then PSA 
failure was assigned at time zero. Patients with no follow-up PSA measurements (N=190, 
14.5%) were included for the evaluation of differences in preoperative and pathologic 
characteristics, but not for analysis on FFbF outcomes.
Statistical analysis
Clinical and pathologic variables were compared across the race groups using an analysis of 
variance model for continuous variables or contingency table χ2 test of homogeneity for 
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categorical variables. Predictors of adverse pathologic features were examined using logistic 
regression models. Age, PSA, and year of surgery were examined as continuous variables. T-
stage (T1a-c vs. T2), biopsy GS, and race were examined as categorical variables. Based on 
pathologic findings following surgery, patients were further stratified using the Cancer of the 
Prostate Risk Assessment post-Surgery (CAPRA-S), a validated post-surgical score that 
predicts risk of a cancer recurrence following RP[12]. Variables for determining CAPRA-S 
score included preoperative PSA, pathologic GS, SM, EPE, and SVI. Patients were 
categorized into low (CAPRA-S <3), intermediate (CAPRA-S 3–5) and high (CAPRA-S >5) 
risk of recurrence.
For survival analysis, the primary event of interest was PSA failure (biochemical disease 
recurrence). Individuals who did not experience PSA failure were censored at the time of 
last PSA measurement <0.2 ng/dl, or loss to follow-up. Time to PSA failure was used as a 
surrogate for freedom from biochemical failure (FFbF). The FFbF rates were compared 
across the groups using a log-rank survivorship and Kaplan-Meier analyses. For multivariate 
analysis, a forward-stepwise Cox proportional hazards model was used with p<0.2 
determining which variables were entered into the model at each step. The variable with the 
highest p value was successively deleted until only variables with p<0.2 remained. Analyses 
were conducted using STATA statistical software version 13.0 (STATA Corporation). This 
study was approved by our Institutional Review Board.
Results
Baseline clinical and pathologic characteristics of overall cohort are listed in Table 1. 
Preoperative factors such as age at RP, PSA at diagnosis, and clinical T-stage were similar 
between groups. Compared with CS men, AA men had higher biopsy GS (p<0.001). There 
was no difference in ≥1 adverse pathologic features among race groups (28% vs. 31%; 
p=0.41). However, a greater number of AA men had pathologic GS of ≥7 (52% vs. 43%; 
p=0.01), as well as SVI (6% vs. 3%; p=0.02). There was no difference in use of radiotherapy 
or ADT between groups.
Using the Kaplan-Meier survival analysis method, the impact of race on FFbF was evaluated 
in the overall cohort. The mean and median follow-up time from RP date until last follow-up 
PSA date was 45 months and 27 (range 1 to 207) months respectively. During this time 
period, 144 patients (11.5%) experienced biochemical failure. The 7-year FFbF rate between 
CS men and AA men was 86% versus 79%, respectively (Fig. 1; p=0.035). There was no 
difference in adverse pathologic features using the validated CAPRA-S score for risk of 
recurrence, (Fig. 2A; p=0.28). However, the corresponding Kaplan-Meier estimates of FFbF 
showed worse outcomes among AA men in the CAPRA-S <3 group, Fig. 2B (p=0.01). 
There was no statistically significant difference in the CAPRA-S 3–5 and >5 risk groups 
likely due to small numbers in both groups (Fig. 2B; p=0.67 and p=0.19), respectively.
Using a Cox proportional hazard model, the predictors of FFbF following RP were 
determined, (Table 2). In the multivariate model of overall cohort, T stage (HR 2.92, 95%CI 
1.17–7.32; p=0.02) serum PSA (HR 1.14, 95%CI 1.09–1.20; p<0.001), clinical GS (HR 
1.51, 95%CI 1.01–2.27; p=0.045), pathologic GS (HR 1.59, 95%CI 1.18–2.15; p=0.002), 
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EPE (HR 2.01, 95%CI 1.33–3.04; p=0.001), SVI (HR 2.47, 95%CI 1.48–4.12; p=0.001), 
and SM (HR 1.7, 95%CI 1.13–2.56; p=0.01) were predictors of FFbF.
In order to study outcomes in men with prostatectomy-proven low-grade PCa, we analyzed 
the characteristics of 705 men (112 AA, and 593 CS) who had pathologic GS ≤6 (i.e. low-
grade disease) following RP, using similar analytic methods employed in the overall cohort. 
For this analysis patients who initially had biopsy Gleason <7 and then upon RP were 
upgraded to pathologic Gleason grade ≥7 were excluded. This represents a true cohort of 
patients with low-grade disease. In this cohort, there was no difference in any pre- and post-
treatment characteristics between race groups among patients with low-grade disease (Table 
3). To determine the effect of race on FFbF we analyzed this cohort with low-grade disease 
with similar CAPRA-S score. This group received prostatectomy as monotherapy with <5% 
needing any additional therapy, (Table 3). Among patients with low-grade disease, AA men 
demonstrated worse 7-year FFbF (Fig. 3A; p=0.002), despite similar CAPRA-S score 
compared with CS men (Fig. 3B; p=0.90).
Using a multivariate model, the significant predictors of risk for FFbF following RP were 
determined for patients with low-grade disease, (Table 4). Serum PSA (HR 1.24, 95%CI 
1.15–1.34; p<0.001), EPE (HR 3.77, 95%CI 1.79–7.95; p<0.001), and AA race (HR 2.01, 
95%CI 1.08–3.72; p=0.029) remained predictors of FFbF.
Discussion
In this report, we show that AA men with low-grade disease have worse FFbF as compared 
with their CS counterparts (Fig. 3A). This observation is not likely due to treatment 
differences since patient groups had similar adverse pathologic features as demonstrated by 
comparable CAPRA-S scores between AA and CS men (Fig. 3B) and there were no 
differences by race in the utilization of adjuvant radiotherapy or ADT. Additionally, there 
was no difference in extent of positive margin status by race to suggest sub-optimal surgical 
technique in AA patients (Table 3). Less than 5% of entire cohort had documented treatment 
with additional RT or ADT. This data may reflect the low physician referral patterns for 
adjuvant treatment for eligible patients [13, 14]. However, these results should be interpreted 
with caution, since a number of patients may have undergone RP at UPHS and then received 
RT at another institution.
Overtreatment of GS ≤6 PCa diagnosed on biopsies triggered by elevated PSA remains an 
ongoing controversy[15]. In fact, a few recent studies have suggested that removing the label 
“cancer” from biopsy GS ≤6 disease could potentially reduce overtreatment of low-grade 
disease[16, 17]. However, our results suggest caution in applying this to some men, and 
particularly AA men. Biopsy GS alone usually underestimates both grade and extent of 
disease, thus relabeling of biopsy GS ≤6 disease as non-cancer could result in a missed 
opportunity of curative treatment in some individuals. Consistent with our study (Table 1), 
the rate of upgrading from biopsy GS ≤6 to pathologic GS ≥7 at prostatectomy is estimated 
at 25% to 35%[18]. A number of studies have shown a suboptimal correlation between 
biopsy Gleason scoring and radical prostatectomy, despite the migration from sextant 
biopsies to 12-core sampling. Cookson et, al. showed that biopsy GS was identical to 
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specimen core in 31% of cases, while discrepant by >2 GS in 26%[19]. In more 
contemporary series utilizing 12 or more biopsy cores, the upgrade rate is approximately 
30%[20]. Furthermore, there is evidence to suggest that the zonal distribution of cancer foci 
within the prostate may differ between AA and CS men, thus influencing the result of core 
biopsies[21]. Therefore, the current practice of recommending no active treatment for 
patients by relying heavily on parameters such as biopsy grade, number of biopsy positive 
cores, and initial PSA may need to be validated in AA men.
As per the NCCN guidelines, active surveillance (AS) is the preferred treatment option for 
men with very low-risk PCa and life expectancy of ≤20 years or those with low-risk disease 
and life expectancy of less than 10 years[22]. The advantage of AS is to prevent 
overtreatment of indolent disease while actively monitoring the course of the disease and 
intervene only when progression occurs in patients with more aggressive disease[23]. 
However, evidence for the benefit of AS was based on studies conducted in primarily CS 
cohort[24, 25]. In studies where race was reported 5% to 10% of patients enrolled in AS 
program were African-American[20, 26]. One retrospective study evaluated the effect of 
race on discontinuation of AS for patients with low-risk PCa. Their results showed that AA 
men had more aggressive disease and were more likely to progress on AS, and proceed to 
treatment faster than CS men[27]. A large study on pathologic and FFbF outcomes in very 
low-risk AA men who qualify for AS but underwent immediate RP showed that AA men 
had significantly higher rates of upgrading, positive surgical margins, and CAPRA-S score 
than do CS men[28]. Data from our study however, showed worse FFbF even in AA patients 
despite similar CAPRA-S score and low-grade disease when compared to their CS 
counterparts (Fig. 2,3). Potential reasons for the discrepancy in pathologic outcomes 
between our low-grade study and the prior study is likely due to the fact that, unlike the prior 
study that evaluated low-risk patients as determined by biopsy Gleason grade, we analyzed a 
cohort of patients with truly low-grade (pathologic Gleason grade ≤6) disease. Nonetheless, 
these emerging data suggests that further study is needed to determine whether some AA 
men with low-grade disease and CAPRA-S score of >2 may derive benefit from additional/
adjuvant therapy such as radiation or ADT. In light of these findings, AA men found to have 
biopsy GS ≤6 with clinically low-risk disease who choose AS should undergo more careful 
monitoring due to possibility of increased oncologic risk.
Of note, several studies have been conducted regarding the effect of race on FFbF after 
definitive PCa treatment with radical prostatectomy (RP), or radiotherapy. However, results 
from these studies have proven inconclusive[28–30]. These inconsistencies may in part be 
due to differences in selection criteria and imbalances in comparison groups.
The strength of our study is that it provides a stringent analysis of AA and CS men with 
similar adverse pathologic features. Therefore, known socio-economic factors such as 
inaccessibility to healthcare, late diagnosis, and sub-optimal treatment are less likely account 
for outcomes disparity in this cohort. Our data has major clinical implications for treatment 
recommendations, which includes potentially undertreating low-grade disease in AA men. 
Furthermore, AA men with low-grade disease need to be enrolled on clinical trials 
evaluating biomarker driven risk-adapted treatment options to improve outcomes.
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A major limitation to this study is that it has a relatively small number of AA compared with 
CS men, and represents the experience from a single tertiary center. Though the men in this 
study had identical adverse pathologic risk features, a randomized controlled trial is required 
to adequately answer the question of race and FFbF outcomes in men with low-grade 
disease. Outcomes were not adjusted for socioeconomic factors, diet, obesity, comorbid 
conditions, and adherence to treatment recommendations. Information on tumor volume or 
percentage of cores positive for tumor were inconsistently reported, and hence we could not 
adequately investigate outcomes in very low-risk patients who might have been eligible for 
active surveillance.
In conclusion, AA race is a predictor of worse FFbF in patients with pathologic GS ≤6 or 
low-grade disease and favorable pathologic features. This highlights the need for clinically 
useful biomarkers that will enable us to identify AA men appropriate for active surveillance 
vs. those harboring aggressive disease that may ultimately benefit from exploration of 
additional/adjuvant therapy such as radiation or ADT.
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FIGURE 1. 
Kaplan-Meier curves for FFbF outcomes by race in NCCN Low–& intermediate- risk men 
undergoing radical prostatectomy at University of Pennsylvania, 1990–2012 (Overall 
Cohort).
Abbreviations: FFbF- Freedom From biochemical Failure, NCCN- National Comprehensive 
Cancer Network P values derived from the Mantel-Cox log-rank test.
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FIG. 2. 
(A). Distribution of CAPRA-S score grouping by race and (B) Kaplan-Meier curves for 
FFbF outcomes by race stratified by CAPRA-S score group in NCCN low- & intermediate- 
risk men undergoing radical prostatectomy at University of Pennsylvania, 1990–2012 
(overall cohort).
Abbreviations: FFbF- Freedom From biochemical Failure, NCCN- National Comprehensive 
Cancer Network, CAPRA-S- Cancer of the Prostate Risk Assessment Post-Surgical scoring 
system
Yamoah et al. Page 11
Urol Oncol. Author manuscript; available in PMC 2016 August 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FIG. 3. 
(A, B) Kaplan-Meier curves for FFbF outcomes and CAPRA-S score grouping by race in 
men with pathologic Gleason ≤6 following radical prostatectomy at University of 
Pennsylvania, 1990–2012.
Abbreviations: FFbF- Freedom From biochemical Failure, CAPRA-S- Cancer of the 
Prostate Risk Assessment Post-Surgical scoring system
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Table 2
Univariate and multivariate regression models of factors predicting FFbF in NCCN low–& intermediate- risk 
men undergoing radical prostatectomy at University of Pennsylvania, 1990–2012 (Overall Cohort).
Univariate analysis HR 95% CI p-Value
Age 0.99 0.96 to 1.01 0.48
Race 1.43 0.99 to 2.05 0.05
Serum PSA 1.16 1.11 to 1.21 <0.001
T-stage 3.79 1.55 to 9.26 0.003
Clinical gleason score 2.63 1.80 to 3.83 <0.001
Year of prostatectomy 1.04 0.99 to 1.08 0.09
Extraprostatic spread 3.89 2.81 to 5.38 <0.001
Positive surgical margins 3.72 2.67 to 5.19 <0.001
Seminal vesicle invasion 5.9 3.71 to 9.38 <0.001
Pathologic gleason score 2.63 2.01 to 3.44 <0.001
Multivariate analysis
Age 0.99 0.96 to 1.02 0.50
Race 1.38 0.92 to 2.07 0.12
Serum PSA 1.13 1.08 to 1.19 <0.001
T-stage 2.92 1.17 to 7.32 0.02
Prostate specific antigen 1.14 1.09 to 1.20 <0.001
Extraprostatic spread 2.01 1.33 to 3.04 0.001
Seminal vesicle invasion 2.47 1.48 to 4.12 0.001
Positive surgical margins 1.7 1.13 to 2.56 0.01
Clinical gleason score 1.11 0.69 to 1.79 0.67
Pathologic gleason score 1.59 1.18 to 2.15 0.009
NOTE. Boldfaced values represent statistically signi cant differences between groups.
Abbreviations: PSA- Prostate-specific antigen, NCCN- National Comprehensive Cancer Network, FFbF- Freedom From biochemical Failure
P values derived from a Cox proportional hazards model.
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Table 4
Univariate and multivariate regression models of factors predicting FFbF in men with pathologic Gleason ≤6 
(low-grade disease) following radical prostatectomy at University of Pennsylvania, 1990–2012.
Univariate analysis HR 95% CI p-Value
Age 1.01 0.96 to 1.05 0.63
African-American Race 2.02 1.09 to 3.74 0.025
Serum PSA 1.22 1.06 to 1.41 0.005
T-stage 1.37 0.87 to 2.14 0.17
Clinical Gleason score 2.48 0.76 to 8.19 0.13
Year of prostatectomy 0.99 0.91 to 1.06 0.61
Extraprostatic spread 4.05 2.27 to 7,23 <0.001
Positive surgical margins 3.71 1.94 to 7.04 <0.001
Seminal vesicle invasion 8.1 2.87 to 22.8 <0.001
Multivariate analysis
Age 1.02 0.97 to 1.06 0.44
Year of prostatectomy 0.99 0.92 to 1.07 0.81
Clinical Gleason score 1.23 0.35 to 4.41 0.74
Serum PSA 1.24 1.15 to 1.34 <0.001
Extraprostatic spread 3.77 1.79 to 7.95 <0.001
African-American Race 2.01 1.08 to 3.72 0.029
Seminal vesicle invasion 2.71 0.89 to 8.57 0.089
Positive surgical margins 1.83 0.81 to 4.12 0.15
NOTE. Boldfaced values represent statistically signi cant differences between groups.
Abbreviations: PSA- Prostate-specific antigen, NCCN- National Comprehensive Cancer Network, FFbF- Freedom From biochemical Failure
P values derived from a Cox proportional hazards model.
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